Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients
Status:
Completed
Trial end date:
2019-07-30
Target enrollment:
Participant gender:
Summary
Demonstrate that low dose (3 mg/kg total ) rATG (thymoglobulin) has similar efficacy (delayed
graft function, slow graft function, biopsy proven acute rejection episodes, infections,
hospitalizations, adverse events, graft loss and death) than Basiliximab induction